Retrospective review of pemetrexed with or without platinum in malignant mesothelioma: The Australian 'Special Access Scheme' experience

Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m² or carboplatin AUC = 5 and pemetrexed 500 mg/m² every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma.     

Evaluation of light sources and light guides for use in transurethral surgery

An evaluation of the quality of light sources and guides was carried out in response to a demand that sufficient light intensity should always be available for transurethral procedures when bleeding occurs. A light monitor was developed for the rapid assessment of the source intensity and light guide transmission. A simple test protocol was also developed for routine assessment of the sources and guides and for evaluation of new sources and guides before purchase. The sources and guides were classified in order of merit and coded to permit the selection of those of the highest quality; this guarantees a satisfactory level of illumination during surgery.     

Noninvasive detection of ventricular wall motion by electromagnetic coupling

Radiofrequency coils are used as sensors in various applications such as nuclear magnetic resonance (NMR) imaging and displacement cardiograms (DCGs). In most cases the impedance and the resonant frequency of the coil are monitored to provide the required information. The paper describes the changes in reflected impedance and in resonant frequency of a coil when it is placed near a medium with properties ranging from a lossy dielectric to a pure conductor. The theory of interaction between the coil and the medium is investigated and a model based on the use of vector potentials is developed. One prediction of the theory is that placing the coil over body equivalent saline (lossy dielectric) at 15 MHz results in an increase in the inductance of the coil and a resultant decrease in resonant frequency. This prediction was supported experimentally.     

Absence of an association between HLA-DRB1*04 and rheumatoid arthritis in newly diagnosed cases from the community.

OBJECTIVES--To determine HLA-DR4 and DR1 allele frequencies in a series of patients with newly diagnosed early inflammatory arthritis. METHODS--HLA-DR1 and DR4 frequencies were determined by oligonucleotide typing of 208 patients classified as having either rheumatoid arthritis (RA) or undifferentiated inflammatory polyarthritis. RESULTS--The frequency of occurrence of DR4 in these patients with RA did not differ significantly from that in controls in the United Kingdom (42 v 37%). HLA-DR1 was increased in the group with inflammatory polyarthritis (25 v 18%). CONCLUSIONS--The frequency of DR4 is not increased in newly diagnosed community based patients with RA. This supports the hypothesis that DR4 is less important as a marker for susceptibility to RA than it is for disease persistence or severity.